Livagen

Livagen (Lys-Glu-Asp-Ala, KEDA) is a synthetic tetrapeptide bioregulator developed by Professor Vladimir Khavinson's research group at the St. Petersburg Institute of Biogerontology, specifically targeting hepatic tissue. It represents the liver-specific component of the comprehensive organ-targeted bioregulator system that includes peptides for nearly every major organ system.

The liver is the body's primary metabolic organ - responsible for glucose homeostasis, lipid metabolism, protein synthesis, detoxification, bile production, and immune function. Age-related hepatic decline manifests as reduced regenerative capacity, impaired metabolic efficiency, increased susceptibility to hepatic injury, and progressive fibrosis. The development of Livagen aimed to address these age-related changes through targeted bioregulation of hepatic gene expression.

The fundamental mechanism by which Livagen is proposed to act involves interaction with chromatin - the complex of DNA and histone proteins that governs gene accessibility and expression. Research has demonstrated that Livagen can interact with DNA regulatory sequences in liver cells, particularly with regions that become transcriptionally silenced during aging. This epigenetic reactivation of silenced chromatin regions could restore expression of genes that are progressively downregulated in the aging liver - a direct molecular mechanism for reversing some aspects of hepatic aging at the gene expression level.

The practical applications studied for Livagen span several domains of hepatic medicine. In age-related liver decline, the goal is to maintain hepatocyte identity, proliferative capacity, and metabolic efficiency. In the context of regenerative medicine, the restoration of hepatocyte differentiation gene expression could support liver recovery after injury. In metabolic disease research, the normalisation of hepatic gene expression patterns may help restore proper metabolic regulation.

Livagen is most commonly combined with Pancragen in research protocols targeting the metabolic organ system broadly - as both the liver and pancreas are central to glucose and lipid homeostasis, their bioregulators are complementary. Both peptides are often included in comprehensive Khavinson longevity protocols alongside immune bioregulators (Thymalin, Vilon) and neuroendocrine bioregulators (Epitalon).